MiniMed Group, Inc. reported first-quarter fiscal 2027 results ending July 31, 2026, with worldwide net sales of $843 million, representing 16.6% growth as reported and 15.8% organic growth. U.S. net sales reached $240 million (up 13.1%), while international net sales totaled $603 million (up 18.1%). The company raised its fiscal year 2027 organic revenue growth guidance to approximately 10.5%, up from the prior estimate of 10%, and reaffirmed an adjusted EBITDA margin target of approximately 16%. Key operational highlights include the U.S. launch of MiniMed Flex™ with Simplera™, FDA submission for MiniMed Fit™, CE Mark approval for MiniMed Flex™, completion of Vivera™ pivotal trial enrollment, and IDE approval for a next-gen extended wear sensor. MiniMed Group, Inc. operates in the diabetes technology industry, developing insulin delivery systems, continuous glucose monitors, and related algorithms.

MiniMed Group, Inc. announced that Courtney Nelson Wills resigned as Senior Vice President, General Counsel and Corporate Secretary on July 30, 2026, with her departure effective September 25, 2026 following an eight-week transition period. The company stated the resignation was for personal reasons due to a new role outside the medical device space and not due to any disagreement with management. MiniMed is conducting a search for a successor and remains committed to maintaining strong legal oversight during the transition. MiniMed Group, Inc. operates in the medical technology industry, focusing on diabetes care products.

On June 25, 2026, MiniMed Group, Inc. increased its Board of Directors from nine to 11 members. The company appointed David Endicott, CEO of Alcon, Inc., and Linnea Burman, SVP & President of Neurovascular at Medtronic plc, to the Board effective June 29, 2026. Additionally, the company scheduled its 2026 annual meeting of stockholders for October 9, 2026, with a record date of August 11, 2026. MiniMed Group, Inc. operates in the healthcare industry and provides medical device technology.